Dermata Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Dermata Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.56M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($12.29M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($7.79M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($9.61M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($7.90M) | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | ($3.24M) | Mar 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.77M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($12.51M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($8.04M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($9.67M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($7.86M) | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | ($3.17M) | Mar 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.86M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.53M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $7.98M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $6.94M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $11.62M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $605.5K | Mar 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.64M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.97M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.62M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $922.6K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.52M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $3.78M | Mar 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.22M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.56M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $6.36M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $6.02M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $10.11M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($3.18M) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($210.2K) | Mar 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (80) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (39) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (13) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (80) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (39) | Mar 17, 2025 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.52M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.16M | Mar 26, 2026 |
| FY2022 | Dec 31, 2022 | $6.24M | Feb 21, 2023 |
| FY2022 | Dec 31, 2021 | $10.80M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $530.4K | Mar 28, 2022 |